|
|
|
|
||
Re: EXEL-relevant excerpts from Barclays expert call on prostate cancer and renal cell carcinoma“I would have to agree with this assessment “We note our KOL prefers the sequence of axi + pembro, then cabo/nivo in bone mets patients, and then lenvatinib + pembro.” Really? |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
26647 | Re: EXEL-relevant excerpts from Barclays expert call on prostate cancer and renal cell carcinoma | mathlover | 1 | 3/8/2021 3:45:48 PM |